NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions declared that its Board of Directors has approved a share repurchase program on Friday, March 23rd 2018, which allows the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Emergent Biosolutions Inc (NYSE:EBS) announced its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported $1.21 EPS for the quarter, topping the Zacks' consensus estimate of $0.63 by $0.58. The biopharmaceutical company earned $311.80 million during the quarter, compared to the consensus estimate of $289.16 million. Emergent Biosolutions had a return on equity of 10.05% and a net margin of 0.42%. The company's revenue for the quarter was up 79.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.55 EPS. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Emergent Biosolutions.

Emergent Biosolutions issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.1-1.105 billion, compared to the consensus revenue estimate of $1.11 billion.

6 Wall Street analysts have issued 12-month target prices for Emergent Biosolutions' shares. Their forecasts range from $64.00 to $75.00. On average, they anticipate Emergent Biosolutions' share price to reach $69.00 in the next twelve months. This suggests a possible upside of 23.2% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

Media coverage about EBS stock has trended extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Emergent Biosolutions earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Emergent Biosolutions.

Emergent Biosolutions saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,450,000 shares, an increase of 12.4% from the December 15th total of 2,180,000 shares. Based on an average daily volume of 303,800 shares, the short-interest ratio is presently 8.1 days. Approximately 5.7% of the shares of the stock are short sold. View Emergent Biosolutions' Current Options Chain.

Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), NXP Semiconductors (NXPI), CalAmp (CAMP), Gentherm (THRM), AbbVie (ABBV) and Gilead Sciences (GILD).

Emergent Biosolutions' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.58%), Strs Ohio (0.15%), New York State Teachers Retirement System (0.09%), State of Alaska Department of Revenue (0.06%), Nisa Investment Advisors LLC (0.06%) and Eqis Capital Management Inc. (0.06%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Peregrine Capital Management LLC, Nisa Investment Advisors LLC, Louisiana State Employees Retirement System, First Hawaiian Bank and State of Alaska Department of Revenue. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon, Sue Bailey and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio, New York State Teachers Retirement System, Honkamp Krueger Financial Services Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $56.02.

Emergent Biosolutions has a market capitalization of $2.89 billion and generates $782.40 million in revenue each year. The biopharmaceutical company earns $62.70 million in net income (profit) each year or $2.33 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]